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Introduction
Systemic sclerosis (SSc) is characterized by autoimmu-
nity, microangiopathy, and fibrosis in skin and internal
organs. Endothelial activation is reflected by increased
amounts of circulating endothelial proteins such as von
Willebrand factor (vWf) [1], thrombomodulin [2], and
endothelin [3]. Increased plasma concentrations of vWf,
released from activated endothelial cells, have also been
described in other vasculopathies such as hypertension
[4] and diabetes [5] and are reported to predict diabetic
nephropathy [6], myocardial infarction, and mortality [7,8].
However, the use of vWf as a marker of endothelial activa-
tion has several limitations. The variability is substantial
even among normal subjects [9]. Concentrations of vWf
can be influenced by the adhesive properties of the
molecule and by changes in its clearance. For example,
plasma concentrations of vWf are influenced by ABO
blood groups [10,11]. Furthermore, plasma concentra-
tions are reported to increase after exercise in normal indi-
viduals, a phenomenon which can be considered an
adrenergic-type stress response [12]. Similar findings are
reported in patients with rheumatoid arthritis [13] and in
patients with intermittent claudication [14], possibly in
both conditions an effect of a hypoxic reperfusion injury.
vWf is synthesized as a large, 360-kDa precursor, pro-
vWf, which is cleaved into mature vWf and a 97-kDa
propeptide [15]. Stimulation of exocytosis results in
equimolar amounts of vWf and propeptide. The propep-
tide, which has a circulating half-time of 2–3 h, compared
with >12 h [16] for vWf itself, was recently reported to be
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a more reliable marker of acute endothelial activation [17].
Propeptide concentrations are less influenced by factors
such as blood groups, adhesive properties, and catabolism
and thus show less variability among controls [11]. In a
study of patients with type 1 diabetes [11], we found both
vWf and propeptide to be increased in patients with overt
nephropathy and in patients with microalbuminuria,
whereas only the propeptide was increased in normoalbu-
minuric patients. This suggests that assessment of propep-
tide concentrations is a valuable complement in studies of
endothelial activation and also in chronic vasculopathies.
The purpose of the present study was to compare the
value of vWf propeptide in SSc as a marker of disease
activity with that of vWf. We also related the two different
vWf moieties to other markers of disease activity, includ-
ing aminoterminal type III procollagen peptide (PIIINP)
[18], and to internal organ involvement.
Materials and methods
Patients
Forty-four consecutive patients referred to the Department
of Rheumatology, Lund University Hospital, Sweden, from
January 1995 to July 1996 were included in the study. SSc
was confirmed in 36 of these according to the criteria of
the American College of Rheumatology (ACR) [19].
Twenty-three patients had limited cutaneous systemic scle-
rosis (lSSc), with skin sclerosis limited to extremities and
face [20], and 13 had diffuse cutaneous systemic sclerosis
(dSSc), with skin involvement of the trunk as well. The
remaining eight patients were classified as having sus-
pected systemic sclerosis (suspSSc), with Raynaud phe-
nomenon and sclerodactyly (Supplementary Table 1). They
did not fulfil the ACR criteria for SSc at the time for the
assessment but did so 2 years later. No patient was at the
time of assessment being treated with any putatively
disease-modifying drug. Four patients were being treated
with corticosteroids orally, three of them taking <5 mg per
day and one taking 20 mg per day. Eighteen patients were
being treated with calcium-channel blockers and three with
inhibitors of angiotensin-converting enzyme. Six patients
were smokers (two with dSSc, two with lSSc, and two with
suspSSc). No patients had diabetes.
Based on pulmonary involvement combined with short
disease duration (£1 year), the 36 patients with verified
SSc after the initial assessment were classified into two
groups. Group A consisted of 12 patients with decreased
vital capacity and/or carbon monoxide-diffusing capacity
and disease duration of 1 year or less. Eight of these
patients had dSSc and four had lSSc. Among the lSSc
patients, pulmonary involvement was further stressed by
alveolitis diagnosed by high-resolution computed tomogra-
phy in two patients and pulmonary hypertension by
Doppler cardiography in one patient. Group B consisted
of the remaining 24 patients (Supplementary Table 2).
The assays used are described briefly below, and in more
detail in the Supplementary material.
Propeptide assay
The propeptide was analyzed by enzyme-linked
immunosorbent assay (ELISA) as described elsewhere
[17]. Each sample was tested at four dilutions. Results are
expressed as percentage of a normal plasma pool
(%NPP).
vWf assay
Analysis of vWf was by ELISA, using a rabbit antihuman
vWf antibody (DAKO A082), a monoclonal mouse antihu-
man vWf antibody (DAKO M0616), and a rabbit anti-
mouse Ig conjugated to alkaline phosphatase (DAKO
D0314). The standard error of the mean in healthy con-
trols was 9%. Results in this study are expressed as
%NPP. The same normal plasma pool, comprising eight
healthy nonsmoking persons (two male and six female),
aged 36–76 years (median 54 years), was used in both
methods (propeptide assay in Geneva and vWf assay in
Lund). For all analyses, EDTA plasma was used. Blood
samples were drawn from patients between 09.00 h and
10.00 h after 30 min rest in bed with no smoking.
Capillary abnormalities were analyzed quantitatively by a
computer-based method [21]. The pulmonary artery pres-
sure was measured in 27/44 patients by Doppler cardiog-
raphy [22]. The glomerular filtration rate was determined
by iohexol clearance [23] and expressed as the age-
adjusted percentage of mean values for healthy controls
(%p). Pulmonary function was assessed by vital capacity
as measured by a dry spirometer and by carbon monoxide-
diffusing capacity as measured by the single-breath
method, both expressed as %p. Skin involvement was
assessed by a modified Rodnan score, consisting of stan-
dardized palpation over 24 anatomical sites, using a scale
of 0 to 3, with 0 being normal, 1 being thickened skin,
2 being thickened skin that cannot be pinched, and
3 being hidebound skin [24]. PIIINP was analyzed by
radioimmunoassay (Orion Diagnostica, Espoo, Finland).
The degree of inflammatory activity was determined by the
ESR according to the Westergren method; C-reactive
protein (CRP) and orosomucoid (a1 acid glycoprotein)
were both determined by protein electrophoresis.
Statistics
The statistical significance of difference between two
groups was calculated by the Mann–Whitney U test for
unpaired observations and the Wilcoxon matched pairs
signed ranks test for paired observations. A Kruskal–
Wallis test was used for comparisons among three
groups. The relation between two variables was calcu-
lated with Spearman’s rho.Arthritis Research    Vol 3 No 3 Scheja et al
Results
Plasma concentrations of vWf in 44 SSc patients were
higher than the corresponding concentrations of propep-
tide (P < 0.01; Supplementary Fig. 1). One outlier in vWf,
with a plasma concentration nearly three times higher than
any other observation, was excluded from all calculations.
The range of propeptide values in each patient subgroup
was narrower than that for vWf. The three subgroups
(dSSc, lSSc, and suspSSc) differed in vWf (P < 0.05) but
not in propeptide (P = 0.11). There was a correlation
between vWf and propeptide (rho = 0.36, P < 0.05).
The patients with verified SSc were subgrouped according
to pulmonary involvement and short duration of disease
into groups A and B. The patients in group A had higher
plasma concentrations of propeptide (P < 0.02) than those
in group B, whereas no significant difference was found in
vWf. Table 1 shows biochemical parameters in the two
groups. Orosomucoid concentrations were also higher in
group A, but the difference showed less significance. No
significant difference was found in CRP, ESR, or PIIINP.
The correlation between the propeptide and vWf, respec-
tively, and other biochemical markers of activity was calcu-
lated (Table 2). A closer relation of the propeptide than of
vWf to other markers of activity was found. Both moieties
correlated with skin score (rho = 0.39 and 0.40, respec-
tively) but not with pulmonary function or with kidney func-
tion. vWF but not propeptide correlated inversely with
manifest vascular injury evaluated by capillary density
(P < 0.05, rho = –0.41) and positively with pulmonary pres-
sure (P < 0.05, rho = 0.42). Neither parameter showed any
relation to duration of disease.
Discussion
Increased plasma concentrations of vWf in SSc have
been described in several studies [1,25,26]. Higher con-
centrations in patients with a diffuse form of the disease
[27,28] and in patients with more severe disease [28,29]
are reported. A negative relation to the degree of capillary
abnormalities is also described [25]. However, the useful-
ness of this marker of endothelial activation is limited by
the great variability in normal values [9,11] and by the
great overlap between patients and controls and between
different subgroups of patients. The propeptide has been
reported to be a more reliable marker of acute endothelial
activation than is vWf [11,17].
In the present study of patients with SSc, we found
higher plasma concentrations of vWf than of its propep-
tide, as would be expected in view of the known differ-
ence in the circulating half-times of the substances
[16,17]. However, the propeptide showed a smaller
range in each subgroup. The eight patients with suspSSc
who didn’t fulfil the ACR criteria at the time of the assess-
ment but did so 2 years later are included, because they
represent early cases and might be of special interest
when endothelial activation is studied.
There is a lack of markers of disease activity in SSc. A lack
of correlation between disease activity and CRP has been
shown by Stuart et al [30]. The patients in group A had
significantly shorter duration of disease and more pul-
monary involvement, indicating a more serious and pro-
gressive disease. As expected, the skin score was higher
in group A, because the proportion of patients with dSSc
was higher in this group. The groups differed significantly
in the propeptide but not in vWf. This difference was more
pronounced than with other possible markers of disease
activity: CRP, orosomucoid, and PIIINP. These results
were further underscored by more pronounced correla-
tions between propeptide and various markers of activity
Table 1
Biochemical parameters in 35 patients with verified systemic
sclerosis, grouped according to pulmonary involvement and
duration of disease
Biochemical Group  Aa Group Ba
parameter n = 12 n = 23
Propeptide (%NPP) 150 120  P < 0.02
(87–360) (72–167)
vWf (%NPP)  210 146  ns 
(66–670) (58–459) (P = 0.32)
CRP ( mg/l) 11 5  ns 
(5–88) (5–32) (P = 0.052)
Orosomucoid (g/l) 1.07 0.87  P < 0.05
(0.81–1.89) (0.42–1.15)
ESR (mm/h) 21 14  ns 
(2–70) (4–70) (P = 0.12)
PIIINP (µg/l) 5.8 4.0  ns 
(3.0–17.0) (1.5–10.5) (P = 0.07)
Values are shown as median (range). P values indicate the difference
between group A and group B; ns = not significant. aGroup A
consisted of patients with short disease duration (£1 year) and
pulmonary involvement. Group B consisted of the remaining patients.
Table 2
Correlation (Spearman’s rho) of plasma concentrations of vWf
propeptide and vWf with various biochemical parameters of
activity
Biochemical parameter  Propeptide vWf
PIIINP 0.61** 0.35*
Orosomucoid 0.60** 0.29 ns
CRP 0.21 ns 0.10 ns
ESR 0.56** 0.27  ns
*  P < 0.05; ** P < 0.01; ns = not significant.than between vWf and these markers. The absence of a
correlation between vWf and CRP was also found by
Blann et al [31]. The correlation of vWf and propeptide
with skin score indicates a relation between endothelial
activation and skin fibrosis. No correlation with pulmonary
or kidney function was seen, probably because these
patients had the disease for a short time and internal
organ involvement was relatively discrete. In an earlier
study [32], we found an inverse correlation between the
glomerular filtration rate and vWf and a negative relation
between pulmonary pressure and vWf in a small number
of patients with isolated pulmonary hypertension. In the
present study, the low proportion of patients with a
decreased glomerular filtration rate (6/48) probably pre-
cludes the detection of any correlation.
This study showed lower plasma concentrations of
propeptide than of vWf in patients with SSc but less vari-
ability within patient subgroups. The difference between
patients with early pulmonary involvement compared with
the others was more pronounced in propeptide compared
with vWf and with other biochemical markers. The relation
between propeptide and other markers of biochemical
activity was more pronounced than for vWf. These results
indicate that the propeptide concentrations might be more
useful than vWf in the assessment of disease activity in
patients with SSc.
Acknowledgements
Supported by grants from the Österlund Foundation, the Koch Founda-
tion, The Medical Faculty of the University of Lund, the Medical
Research Council (project no K97-19X-11628-02B), Sweden; and the
Swiss National Science Foundation (grant 32-52667.97), Switzerland.
We thank Mrs Jean Gunn for critical reading of the manuscript.
References
1. Kahaleh MB, Osborn I, LeRoy EC: Increased factor VIII/von
Willebrand factor antigen and von Willebrand factor activity in
scleroderma and in Raynaud’s phenomenon. Ann Int Med
1981,  94:482–484.
2. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N: Plasma
thrombomodulin as a marker of vascular injuries in collagen
vascular diseases. Am J Clin Pathol 1994, 101:109–113.
3. Kahaleh MB: Endothelin, an endothelial-dependent vasocon-
strictor in scleroderma: enhanced production and profibrotic
action. Arthritis Rheum 1991, 34:978–983.
4. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G,
Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, et al:
Microalbuminuria and endothelial dysfunction in essential
hypertension. Lancet 1994,  344:14–18.
5. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T: Fea-
tures of endothelial dysfunction in early diabetic nephropathy.
Lancet 1989, i:461–463.
6. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polak BCP,
Donker AJM: Endothelial dysfunction precedes development
of microalbuminuria in IDDM. Diabetes 1995, 44:561–564.
7. Jansson J-H, Nilsson TK, Johnson O: Von Willebrand factor in
plasma: a novel risk factor for recurrent myocardial infarction
and death. Br Heart J 1991, 66:351–355.
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo
JCV: Hemostatic factors and the risk of myocardial infarction
or sudden death in patients with angina pectoris. N Engl J
Med 1995,  332:635–641.
9. Ingerslev J: A sensitive ELISA for von Willebrand factor
(vWF:Ag). Scand J Clin Lab Invest 1987, 47:143–149.
10. Cox Gill J, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery
RR: The effect of ABO blood group on the diagnosis of von
Willebrand disease. Blood 1987, 69:1691–1695.
11. Vischer UM, Emeis JJ, Bilo HJG, Stehouwer CDA, Thomsen C,
Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J: Von
Willebrand factor (vWf) as a plasma marker of endothelial
activation in diabetes: improved reliability with parallel deter-
mination of the vWf propeptide (vWf:AgII). Thromb Haemost
1998,  80:1002–1007.
12. Cohen RJ, Cohen LS, Epstein SE, Dennis LH: Alterations of
fibronolysis and blood coagulation induced by exercise, and
the role of beta-adrenergic-receptor stimulation. Lancet 1968,
ii:1264–1266.
13. Farrel AJ, Williams RB, Stevens CR, Lawrie AS, Cox NL, Blake
DR:  Exercise induced release of von Willebrand factor:
evidence for hypoxic reperfusion microvascular injury in
rheumatoid arthritis. Ann Rheum Dis 1992, 51:1117–1122.
14. Edwards AT, Blann AD, Suarez-Mendez VJ, Lardi AM, McCollum
CN: Systemic responses in patients with intermittent claudi-
cation after treadmill exercise. Br J Surg 1994, 81:1738–1741.
15. Vischer UM, de Moerloose P: Von Willebrand factor: from cell
biology to the clinical management of von Willebrand’s
disease. Crit Rev Oncol Hematol 1999, 30:93–109.
16. Borchiellini A, Fijnvandraat K, Wouter ten Cate J, Pajkrt D, van
Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink
L, Voorberg J, van Mourik JA: Quantitative analysis of von
Willebrand factor propeptide release in vivo: effect of experi-
mental endotoxemia and administration of 1-deamino-8-D
arginine vasopressin in humans. Blood 1996, 88:2951–
2958.
17. Vischer UM, Ingerslev J, Wollheim CB, Mestries J-C, Tsakiris DA,
Haefeli WE, Kruithof EKO: Acute von Willebrand factor secre-
tion from the endothelium in vivo: assessment through
plasma propeptide (vWf:AgII) levels. Thromb Haemost 1997,
77:387–393.
18. Scheja A, Åkesson A, Hørslev-Petersen K: Serum levels of
aminoterminal type III procollagen peptide and hyaluronan
predict mortality in systemic sclerosis. Scand J Rheumatol
1992,  21:5–9.
19. Masi A, Rodnan G, Medsger T, Altman RD, d’Angelo WA, Fries
JF, LeRoy C, Kirsner A, MacKenzie A, McShane D, Myers A,
Sharp G: Preliminary criteria for the classification of systemic
sclerosis (scleroderma). Arthritis Rheum 1980, 23:581–590.
20. LeRoy C, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger
T, Rowell N, Wollheim F: Scleroderma (systemic sclerosis):
classification, subsets and pathogenesis. J Rheumatol 1988,
15:202–205.
21. Scheja A, Åkesson A, Niewierowicz I, Wallin L, Wildt M, Wollheim
FA: Computer based quantitative analysis of capillary abnor-
malities in systemic sclerosis and its relation in plasma con-
centration of von Willebrand factor. Ann Rheum Dis 1996, 55:
52–55.
22. Skjaerpe T, Hatle L: Noninvasive estimation of systolic pres-
sure in the right ventricle in patients with tricuspid regurgita-
tion. Eur Heart J 1986, 7:704–710.
23. Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clear-
ance of a new contrast agent, iohexol: a method for the
assessment of glomerular filtration rate. J Lab Clin Med 1984,
104:955–961.
24. Åkesson A, Wollheim FA: Organ manifestations in 100 patients
with progressive systemic sclerosis: a comparison between
the CREST syndrome and diffuse scleroderma. Br J Rheuma-
tol 1989, 28:281–286.
25. Lee P, Norman CS, Sukenik S, Alderdice CA: The clinical signifi-
cance of coagulation abnormalities in systemic sclerosis
(scleroderma). J Rheumatol 1985, 12:514–517.
26. Pagano L, Marra R, Paoletti S, Afa G, Storti S, Garcovich A, Bizzi
B: Factor VIII complex in progressive systemic sclerosis. Clin
Exp Rheumatol 1986, 4:319–321.
27. Blann AD, Illingworth KJ, Jayson MIV: Raised concentrations of
von Willebrand factor antigen in systemic sclerosis. Ann
Rheum Dis 1991, 50:337–338.
28. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV:
Von Willebrand factor, thrombomodulin, tromboxane, b b-
thromboglobulin and markers of fibrinolysis in primary Ray-
naud’s phenomenon and systemic sclerosis. Ann Rheum Dis
1996, 55:122–127.
Available online http://arthritis-research.com/content/3/3/178
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
hArthritis Research    Vol 3 No 3 Scheja et al
29. Greaves M, Malia RG, Milford Ward A, Moult J, Holt CM, Lindsey
N, Hughes P, Goodfield M, Rowell NR: Elevated von Willebrand
factor antigen in systemic sclerosis: relationship to visceral
disease. Br J Rheumatol 1988, 27:281–285.
30. Stuart RA, Littlewood AJ, Maddison PJ: Elevated serum inter-
leukin-6 levels associated with active disease in systemic
connective tissue disorders. Clin Exp Rheumatol 1995, 13:
17–22.
31. Blann AD, Herrick A, Jayson MIV: Altered levels of soluble
adhesion molecules in rheumatoid arthritis, vasculitis and
systemic sclerosis. Br J Rheumatol 1995, 34:814–819.
32. Scheja A, Eskilsson J, Åkesson A, Wollheim FA: Inverse relation
between plasma concentration of von Willebrand factor and
CrEDTA clearance in systemic sclerosis. J Rheumatol 1994,
21:639–642.
Supplementary material
Materials and methods
Propeptide assay
The vWf propeptide was analyzed by ELISA as described
elsewhere [17]. Briefly, 96-well plates were coated with
the monoclonal antipropeptide antibodies BR5 and 3H4,
0.75 mg/ml each, in carbonate buffer (NaHCO3, 50 mM,
pH 9.6). After the remaining protein binding sites were
blocked with 5% (w/v) dry skimmed milk, the samples and
standards, diluted in blocking solution, were added and
incubated for 2 h at 37°C. The bound antigen was
detected with a third, antipropeptide, monoclonal antibody
(8H10) conjugated to alkaline phosphatase diluted to
approximately 0.25 mg/ml. Alkaline phosphatase activity
was detected using p-nitrophenyl phosphate as a sub-
strate and measuring the optical density at 405 nm. Each
sample was tested at four dilutions. Results are expressed
as percentage of a normal plasma pool (%NPP).
vWf assay
vWf was analyzed by an ELISA. For this, 96-well plates
(Nunc-Immuno Maxisorp, Roskilde, Denmark) were coated
overnight at 4ºC with rabbit antihuman vWf antibody
(DAKO A082) diluted 1:400 in phosphate-buffered saline
(PBS). The plate was then washed (3 × 2 min) with
PBS–Tween (0.5% Tween 20). To avoid measuring possi-
ble rheumatoid factor activity in the samples, all wells were
incubated with normal rabbit IgG (DAKO X903) diluted
1:100 in PBS for 30 min at room temperature. The plates
were washed, and 0.5% gelatin in PBS was added for 30
min incubation at room temperature to block remaining
protein-binding sites. The plates were washed again, the
samples were diluted 1:50 in PBS–Tween, added in dupli-
cates to the plates, and incubated for 2 h at room tempera-
ture. After another washing, a monoclonal mouse
antihuman vWf antibody (DAKO M0616) was added,
diluted 1:2000 in PBS–Tween, and incubated for 30 min
at room temperature. After washing, rabbit antimouse
immunoglobulin conjugated to alkaline phosphatase
(DAKO D0314) 1:1000 in PBS–Tween was added. Alka-
line phosphatase activity was detected using p-nitrophenyl
phosphate as a substrate and measured at dual wave-
length (405 and 690 nm). At development of this ELISA,
the concentration of vWf was determined against standard
curves of Haemate (Hoechst, Marbourg, Germany), a com-
mercially available vWf concentrate. The lower detection
limit of the ELISA was 1.6 IE/ml. Both interassay and intra-
assay variations were less than 10%. Results in the present
study are expressed as %NPP. The same normal plasma
pool comprising eight healthy persons (two male and six
female), aged 36–76 years (median 54 years), was used in
both methods (propeptide assay in Geneva and vWf assay
in Lund). For all analyses, EDTA plasma was used. Blood
samples were drawn from patients between 09.00 h and
10.00 h after 30 min rest in bed with no smoking.
Supplementary Figure 1
Plasma levels of vWf and its propeptide in 44 patients with SSc,
grouped according to the degree of skin involvement. Medians are
marked with horizontal bars.
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Supplementary Table 2
Clinical characteristics of 35 patients with verified systemic sclerosis, grouped according to pulmonary involvement and duration
of disease.
Group A (n = 12) Group B (n = 23)
Median Range (SEM) Median Range (SEM)
dSSc/lSSc 8/4 5/18
ACA/antiScl70 0/0 14/1
Age (y) 57 26–75 (4.7) 49 25–76 (2.8) ns
Disease duration (y) 1 1–1 (0) 2 1–49 (2.3) P < 0.01
Skin score (points) 26 3–36 (3.2) 8 2–26 (1.6) P < 0.01
VC (%p) 77 51–113 (5.6) 97 62–148 (3.8) P < 0.05
DLCO (%p) 62 40–90 (4.9) 85 47 –116 (3.7) P < 0.01
PAPsyst (mmHg) 36 27–65 (3.9) 30 18–59 (3.4) ns
GFR (%p) 103 89–130 (5.4) 96 70–136 (4.1) ns
Capillary density (loops/mm) 4.2 2.4–6.9 (0.6) 5.5 2.2–8.4 (0.4) ns
DLCO, carbon monoxide-diffusing capacity; GFR, glomerular filtration rate; PAPsyst, systolic pulmonary artery pressure; VC, vital capacity. P values
indicate the difference between group A and group B. ns = Not significant.
Supplementary Table 1
Clinical characteristics of 44 patients with systemic sclerosis, grouped according to the skin involvement
Disease form dSSc lSSc suspSSc
No. 13 23 8
Sex (F/M) 12/1 21/2 8/0
Normal 
Median Range (SEM) Median Range (SEM) Median Range (SEM) values
Age (y) 49 27–75 (4.0) 56 18–76 (3.3) 51 20–67 (6)
Duration (y) 1 1–7 (0.46) 2 1–49 (2.4) –
Skin score (points) 26 15–36 (1.7) 5 2–15 (0.81) 3 2–4 (0.3) 0
VC (%p) 97 61–148 (6.3) 94 51–120 (3.8) 99 84–130 (6.0) 80–120
DLCO (%p) 77 46–111 (6.0) 77 40–116 (4.3) 86 67–105 (5.4) 80–120
PAPsyst (mmHg) 36 20–43 (2.9) 30 18–65 (3.5) 28 24–34 (1.6) £32
GFR (%p) 109 94–130 (4.6) 95 70–136 (3.8) 101 93–114 (2.6) 80–120
Capillary density (loops/mm) 5.1 2.9–8.3 (0.7) 4.5 2.2–8.4 (0.4) 6.9 5.7–7.4 (0.3) 7.5–11.2
ESR (mm/h) 18 2–70 (6.3) 14 4–70 (3.2) 12.5 2–33 (4.3) <20
CRP (mg/l) 6.5 5–88 (6.9) 5 5–32 (1.2) 5 5–26 (2.6) <5
Orosomucoid (g/l) 0.94 0.70–1.89 (0.11) 0.87 0.42–1.63 (0.53) 0.76 0.45–1.13 (0.09) 0.55–1.05
DLCO, carbon monoxide-diffusing capacity; GFR, glomerular filtration rate; PAPsyst, systolic pulmonary artery pressure; VC, vital capacity; 
%p, % of predictive value.